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Review article
Endocrine problems in children with Prader-Willi syn-
drome: special review on associated genetic aspects 
and early growth hormone treatment
Prader-Willi syndrome (PWS) is a complex multisystem genetic disorder 
characterized by hypothalamic-pituitary dysfunction. The main clinical 
features include neonatal hypotonia, distinctive facial features, overall 
developmental delay, and poor growth in infancy, followed by overeating 
with severe obesity, short stature, and hypogonadism later in develop-
ment. This paper reviews recent updates regarding the genetic aspects 
of this disorder. Three mechanisms (paternal deletion, maternal disomy, 
and deficient imprinting) are recognized. Maternal disomy can arise 
because of 4 possible mechanisms: trisomy rescue (TR), gamete com-
plementation (GC), monosomy rescue (MR), and postfertilization mitotic 
nondisjunction (Mit). Recently, TR/GC caused by nondisjunction at 
maternal meiosis 1 has been identified increasingly, as a result of 
advanced maternal childbearing age in Korea. We verified that the 
d3 allele increases the responsiveness of the growth hormone (GH) 
receptor to endogenous GH. This paper also provides an overview 
of endocrine dysfunctions in children with PWS, including GH defi-
ciency, obesity, sexual development, hypothyroidism, and adrenal 
insufficiency, as well as the effects of GH treatment. GH treatment 
coupled with a strictly controlled diet during early childhood may help 
to reduce obesity, improve neurodevelopment, and increase muscle 
mass. A more active approach to correct these hormone deficiencies 
would benefit patients with PWS.
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The main clinical features include neonatal hypotonia, distinctive 
facial features, delayed overall development with mental deficiency, 
behavioral abnormalities, and poor growth in infancy, followed by 
overeating with severe obesity, short stature, and hypogonadism later 
Introduction
Prader-Willi syndrome (PWS) is a complex multisystem genetic 
disorder characterized by hypothalamic-pituitary dysfunction
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during development
3). Both the genetic and endocrine aspects of 
this condition have garnered interest, with growth hormone (GH) 
therapy receiving particular attention in recent years. Our aim is to 
provide an update on the recent findings regarding the genetic aspects 
of PWS, a thorough analysis of endocrine dysfunction in PWS (GH 
deficiency, obesity, sexual development, hypothyroi  dism, and adrenal 
insufficiency), and the therapeutic effects of GH treatment.
Genetics of PWS 
The various genetic changes that cause PWS also lead to the loss 
or failure of expression of paternally expressed genes on chromosome 
15q11.2-q13; this is because the maternal contribution has been 
programmed by epigenetic factors (e.g., DNA methylation) to be sil-
enced
4). Three mechanisms have been described: paternal deletion, 
maternal uniparental disomy (mUPD), and deficient imprinting
3). 
Parent-of-origin-specific DNA methylation can be used to confirm 
the clinical diagnosis of PWS patients of all 3 molecular classes. The 
most widely used DNA methylation test targets the 5' end of the 
small nuclear ribonucleoprotein polypeptide N (SNRPN) locus
5,6). 
Normal individuals have both a methylated and an unmethylated 
allele, whereas individuals with PWS have only the maternally me-
thylated allele. 
1. Microdeletion of the chromosome region 15q11-q13
De novo deletion of the proximal region of the paternal chro-
mosome 15 [del(15)(q11-q13)] is found in the majority (-70%) of 
patients with PWS. The deletion type is typically diagnosed using the 
SNRPN fluorescent in situ hybridization probe
4). Testing for a deletion 
should include chromosome analysis, as the deletion is occasionally the 
result of a chromosomal translocation.
2. Uniparental disomy of chromosome 15
The second most common genetic abnormality in PWS (-25 to 30%) 
is an mUPD of chromosome 15. mUPD prevents the expression of 
imprinted genes that are active only on the paternal chromosome and 
is diagnosed using DNA polymorphism analysis of the proband and 
parental DNA. Four possible mechanisms can give rise to mUPD: 
trisomy rescue (TR), gamete complementation (GC), monosomy 
rescue (MR), and postfertilization mitotic nondisjunction (Mit). TR/
GC is caused by nondisjunction at maternal meiosis 1 (M1) or 2 (M2), 
and M1 errors are associated with increased maternal age. 
3. Imprinting defect
Disruption of the imprinting process on the paternally inherited 
chromosome 15 is the third molecular mechanism underlying PWS 
(2 to 5%). Most imprinting defects are epigenetic (epimutations) 
and exhibit a maternal-only DNA methylation pattern, despite 
the presence of both parental alleles. DNA sequence changes are 
not found in these epimutations. By contrast, approximately 15% of 
individuals with an imprinting defect are found to have a very small 
deletion in the PWS imprinting center (IC) region located at the 5' 
end of the SNRPN gene.
4. Classification of the (epi) genetic subtype in Korean PWS 
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Fig. 1. A total of 97 Korean patients with PWS were classified by stepwise molecular tests. PWS, Prader-Willi 
syndrome; IC, imprinting center; FISH, fluorescent in situ hybridization; MA, microsatellite analysis; UPD, uni-
parental disomy; mat, maternal; MLPA, multiplex ligation-dependent probe amplification; CMA, chromosomal 
microarray; [M1]TR/GC, trisomy rescue/gamete complementation resulting from nondisjunction of homo  logous 
chromosome 15s during maternal meiosis I; [M2]TR/GC, trisomy rescue/gamete complementation resulting 
from nondisjunction of the 2 sister (identical) chromatids during maternal meiosis II; MR, monosomy rescue; 
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Recently, we classified a cohort of 97 Korean patients at the Samsung 
Medical Center, comprising 66 PWS patients with deletions and 31 
PWS patients without deletions (Fig. 1). Microsatellite genotyping 
was performed in 23 of the 31 patients without deletions, and 15 pa-
tients were classified in the [M1]TR/GC group, 2 patients in the [M2]
TR/GC group, and 4 patients in the MR/Mit group. Two patients 
were classified as having epimutations because microdeletions 
affecting the PWS IC were not identified by multiplex ligation-
dependent probe amplification or chromosomal microarray. In addi-
tion, we found an increasing tendency for [M1]TR/GC caused by ad-
vanced maternal childbearing age in Korea. The maternal ages were 
significantly higher in the [M1]TR/GC group than in the deletion 
group, which was not associated with any maternal age effect. The 
advanced maternal ages at birth since 2006 were primarily associated 
with the high frequency of [M1]TR/GC. The increased number of 
mUPD PWS births in Korea is thought to represent an advanced 
economy and a trend toward having families later in life. If we assume 
that the number of patients with PWS caused by deletions is not de-
creasing, we would expect a small increase in the incidence of PWS, 
given the increase in the proportion of those with mUPD. 
GH deficiency in PWS 
More than 85% of patients with PWS are have GH deficiency
7). 
Although height at birth is normal, growth velocity is significantly 
decreased after 2 to 3 years, and the mean final adult height is 2 
standard deviation scores below normal
8). Many features of PWS are 
indicative of deficient GH production, including low growth velocity 
despite obesity, reduced lean body mass (LBM), low insulin-like growth 
factor-I (IGF-I) levels, and low insulin levels
7,9). These findings provide 
a rationale for GH therapy in PWS. 
1. Effects of GH therapy
1) Height and growth velocity
With GH therapy, the overall height gain in PWS patients is similar 
to that seen in patients with GH deficiency and is greater than in non-
GH-deficient patients of short stature, even those administered with 
high dosages
10). GH treatment at the currently recommended dosage 
for children with PWS (0.03 mg·kg
-1·day
-1) has been shown to restore 
linear growth and normal final adult height without inducing serious 
adverse effects
11-13). 
2) Body composition 
Low LBM in PWS patients most likely reflects reduced muscle mass 
and may therefore contribute to clinical hypotonia, poor physical 
performance, and, as a result, reduced energy expenditure
7). In a 
randomized controlled GH trial in PWS patients, LBM-corrected for 
height and sex- did not increase during GH treatment but signi  ficantly 
decreased in the control group, suggesting that GH administration 
prevents a reduction in LBM
11). Some studies have reported major 
increases in bone mineral density (BMD) with GH treatment
14). 
Other studies
15,16) suggest a normal total body BMD and no effect of 
GH treatment on total body BMD in young children with PWS.
3) Heart
Cardiac events have been implicated in the sudden death of children 
and young adolescents with PWS, with or without GH treatment
17,18). 
GH secretory status and GH therapy influence cardiac muscle mass 
and function
19). In a retrospective study
20), the response of cardiac 
dimensions to GH treatment was similar in PWS patients and control 
patients with GH deficiency, with a trend towards more elevated left 
ventricular para  meters in PWS patients. Regular echocardiographic 
assessment may be considered for PWS children who undergo 
treatment for a prolonged duration.
2. GH therapy in infants with PWS 
A randomized GH study in infants with PWS showed a 
significant improvement of mental/motor development in the GH 
group as com  pared with the control group
21). IGF-I levels increased 
rapidly during GH treatment from below the normal range to the 
high-normal range. Theoretically, IGF-I may directly influence the 
central nervous system or GH may induce local IGF-I expression 
in brain tissue, thereby improving psychomotor development
21). 
With improved motor de  velopment, children are able to sit, stand, 
and walk independently, and can explore and interact with the 
environment, resulting in subsequent improvement in mental 
development
21). In addition, early GH therapy may significantly 
alter the natural progression of PWS by reducing body fat and 
improving muscle strength, physical function, and lipid profiles 
without resulting in adverse effects
22). Early GH therapy is therefore 
important. At the Samsung Medical Center, nearly 200 patients have 
been diagnosed with PWS, and approximately 100 of these patients 
were diagnosed during infancy. Although children younger than 
2 years are not covered by health insurance in Korea, GH therapy 
has been initiated in recent years in infants after obtaining informed 
consent from their parents. Their growth rate (in terms of height) 
and development (relative to chrono  logic age), have improved with 
GH therapy. Subjectively, the GH-treated infants and toddlers were 
reported by their families to be more alert and energetic. No serious 
side effects have been reported. Conse  quently, we recommend that 
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start of treatment of scoliosis
36). Frequent physical examinations and 
yearly radiographic examinations are recommended, regardless of 
GH treatment. 
3) Obstructive sleep apnea (OSA)
Patients with PWS are also at risk of developing OSA for several 
reasons, including obesity
37), facial dysmorphism (including microg-
na  thia and a small naso- or oropharynx)
38), sticky secretions
39), and 
hy  po  tonia
40). Patients with PWS are reported to have elevated levels 
of adiponectin
5), an adipose tissue-derived hormone, which has 
shown a negative association with OSA syndrome
6). One hypothesis 
proposes an asso  ciation between GH therapy and death during 
upper respiratory in  fections, in which GH treatment may cause 
enlargement of the tonsils and adenoids, which would narrow the 
already small airway of children with PWS
41). Another hypothesis 
maintains that fluid retention early in therapy is the mechanism 
underlying the development of OSA symptoms
42). A pragmatic 
approach in which the balance of benefit versus risk favors treatment 
with GH is to closely monitor each individual for OSA symptoms 
and to repeat the polysomnogram as clinically indicated
43).
4. GH receptor polymorphism and height in children with 
PWS
A common GH receptor (GHR) polymorphism, reflecting the 
presence (fl) or absence (d3) of exon 3, has been under intensive 
investi  gation to determine its influence on response to GH therapy. 
Dos Santos et al.
44) showed that the d3 polymorphism was associated 
with increased responsiveness to GH. A recent study assessed the asso-
ciation of GHR alleles with height before beginning GH therapy in 
patients with PWS
45). Even before GH therapy, the d3 allele appeared 
to increase the responsiveness of GHRs to endogenous GH already 
present in patients with PWS; this response may explain why subjects 
with the d3 allele were taller than those who did not have the allele.
Obesity
1. Nutritional phase 
PWS has been classically described as having 2 nutritional 
stages: failure to thrive in infancy, followed by hyperphagia in later 
childhood. One study described a total of 7 nutritional phases of PWS 
: “Decreased fetal movements and lower birth weight”, “Hypotonia 
with difficulty feeding (0 to 9 months)”, “No difficulty feeding and 
appropriate growth according to growth curves (9 to 25 months)”, 
“Weight increasing without an increase in appetite or excessive calories 
(2.1 to 4.5 years)”, “Weight increasing with an increase in appetite (4.5 
to 8 years)”, “Hyperphagic, rarely feels full (8 years adulthood)”, and 
0.009 to 0.012 mg/kg per day, with subsequent increments during 
the first weeks and months to arrive at the standard replacement GH 
dose of approximately 0.035 mg/kg per day. 
3. Concerns regarding GH therapy
1) Carbohydrate metabolism
Fasting insulin levels have been found to be lower in children with 
PWS than in body mass index (BMI)-matched children with simple 
obesity
10). These low insulin levels suggest increased insulin sensitivity, 
probably related to GH deficiency
7). Adiponectin is an adipokine 
that is primarily secreted from adipocytes; it has been shown to have 
beneficial effects in the prevention of the development of inflammatory 
and atherosclerotic disease
23-25). The effects of adiponectin are 
mediated by adiponectin receptors (ADIPORs), namely ADIPOR1 
and ADIPOR2. Increased expression of ADIPOR2 was found in 
children with PWS 
5), whereas ADIPORs expression in lymphocytes 
was markedly reduced in obese patients
26). These results may account 
for the increased insulin sensitivity in patients with PWS, in contrast 
to insulin resistance ob  served in patients with simple obesity.
In PWS patients, the levels of total ghrelin and acylated ghrelin 
were increased, and these hormones are regulated by insulin. In a study 
on PWS children, acylated ghrelin was sensitively suppressed by insulin 
during an oral glucose tolerance test; this suppression was also cor-
related with insulin sensitivity
27). In contrast, plasma obestatin, a 
peptide hormone derived from the proteolytic cleavage of ghrelin 
preprohormone
28), was not elevated in PWS children and was not 
regulated by insulin in either PWS children or obese controls
28). In-
sulin resistance in children with PWS may be associated with BMI 
even in the absence of GH treatment
29). In a prospective cohort study of 
PWS children
29), despite the favorable effect of GH on body composi-
tion and lipid profile, insulin increased during therapy. Therefore, 
carbohydrate metabolism (glucose and hemoglobin A1c) should be 
closely monitored in patients receiving GH treatment.
2) Scoliosis
Scoliosis, attributed to a combination of obesity and muscular 
hypotonia, is common in both children and adolescents with PWS. 
The prevalence of scoliosis in PWS is high (30% before age 10, 80% 
after age 10)
30-32). The rapid growth associated with GH may aggravate 
this spinal deformity. Some authors have described an association 
between increased GH levels and a higher rate of curve progression in 
children without PWS
33-35). In contrast to these reports, a randomized 
controlled trial in a large group of children with PWS showed no 
significant difference between GH-treated children and randomized 
controls with regard to the onset of scoliosis, curve progression, and 228      DK Jin • Endocrine problems in Prader-Willi syndrome
“Appetite is no longer insatiable (adulthood)”
46). 
2. Mechanism of hyperphagia 
Several theoretical models attempt to explain overeating by 
PWS patients: it is a problem of satiety as opposed to hunger, it is 
a consequence of inner physiological awareness that has potential 
effects on feelings of hunger and satiety, it represents a hyperresponsive 
reward syste m with food as a substance of abuse, it is a direct con-
sequence of genetics on the hypothalamic feeding pathway, and it is 
a consequence of the prenatal environment
47). One study analyzed 
18F-fluorodeoxyglucose positron emission tomography images of PWS 
children and found metabolic abnormalities in brain regions that are 
directly or indirectly related to food intake and obsessive-compulsive 
behavior
48). In recent years, understanding hormonal mechanisms 
that control appetite and eating in PWS patients has generated a lot of 
interest. 
Ghrelin, which stimulates hunger, is principally synthesized in the 
stomach. The number of ghrelin-expressing cells and the amount 
of ghrelin in the gastric body and fundus of PWS patients was 2- to 
3-fold higher than that in control groups
49). However, gastric emptying 
in PWS patients was reduced, despite the higher ghrelin levels, which 
suggests that the voracious appetite associated with PWS is related to 
another mechanism
50). Ghrelin may be involved in the instigation of 
binging and in the hyperphagic stage
47).
3. Importance of early weight control
The weight of patients with PWS begins to increase between 18 
and 36 months of age, without a significant increase in food intake
51), 
that is, the onset of obesity is observed before a substantial increase 
in food intake or interest is seen. Therefore, early management of 
eating behavior is important. At present, the only available control 
for hyperphagia for most people with PWS is close mentoring by 
caregivers and life-long restricted access to food, with food cupboards 
and refrigerators often requiring locks.
Sexual development
1. Hypogonadism
Genital abnormalities, including delayed or incomplete pubertal 
development and infertility, are common in PWS patients of both 
genders. Although some female patients with PWS undergo sponta-
neous menarche, most experience primary or secondary amenorrhea 
or oligomenorrhea. Most clinicians agree that cryptorchidism in male 
patients should be corrected to enable the detection of testicular 
malignancies. Recent findings indicate that hypogonadism in PWS 
patients is not exclusively hypothalamic and that a primary ovarian or 
testicular defect contributes to the abnormal reproductive function
52, 
53). At present, the literature contains few reports regarding the use of 
sex hormone replacement therapy (transdermal or intramuscularly 
administered testosterone preparations for boys and oral or 
transdermal estrogen preparations for girls) in affected individuals, 
although this type of treatment is likely to be beneficial in improving 
secondary sexual characteristics and helping to prevent osteoporosis. 
The need for substitution therapy should be assessed individually 
against the background of the development of BMD, general activity, 
and quality of life.
2. Early adrenarche and precocious puberty
The normal appearance and development of pubic hair (“adrenarche” 
or “pubarche”) suggest unimpaired adrenal androgen secretion, corre-
sponding to the observed normal androstenedione levels. Adrenarche 
typically occurs early in many children with PWS
13,54). True precocious 
puberty is very rare in PWS patients and only a few cases have been 
reported
55). Sexual development is incomplete in most PWS patients, 
and this finding is consistent with arrested pubertal development. 
In patients with PWS who exhibit precocious puberty, the use of a 
luteinizing hormone-releasing hormone analog along with GH can 
permit stature closer to the target height. However, PWS patients 
with precocious puberty need individualized treatment.
Hypothyroidism
Thyroid axis dysfunction seems to be a frequent feature in infants 
with PWS. Pediatricians should be aware of this association so this 
possibility is considered while evaluating PWS patients. Childhood is 
a critical period of thyroid hormone action on neurological develop-
ment, and neonatal thyroid-stimulating hormone (TSH) screening is 
not an accurate tool to diagnose thyroid axis dysfunction
56). Published 
data regarding thyroid hormone levels in PWS children undergoing 
GH therapy are very limited. Free T4, T3, and TSH levels should 
be monitored regularly in PWS children, particularly during GH 
treatment
57).
Adrenal insufficiency
Several reports have indicated an estimated PWS-associated 
mortality rate of 3% yearly
17,18,58,59). Disturbances in the hypothalamus-
hypophysis-adrenal axis are hypothesized to be responsible for this 
mortality rate- or at least to represent concurrent factors consistent 
with an inadequate or late response during infections or relevant 
dehydration episodes
60). Central adrenal insufficiency (CAI) probably 
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secretion by the hypothalamus. In particular, del15 patients, and 
female, obese, and older patients were reported to be at a higher risk 
of CAI
60). Although clinically relevant adrenal failure in PWS children is 
rare, glucocorticoid treatment should be considered during intercurrent 
illness in PWS patients without a recently proven normal adrenal 
function. Cases of moderate-to-severe stress in all PWS infants war-
rant replacement treatment with hydrocortisone at 30 to 70 mg·m
2· 
day
-1, divided into 3 doses
60).
Conclusion
In this review, we attempted to summarize the genetic and 
endocrine dysfunctions in PWS patients and to provide useful 
information for optimizing the management of PWS patients. 
This disorder is a dis  abling condition associated with dysfunction 
of the hypothalamic-pituitary axis and is mainly characterized by 
GH deficiency and hy  pogonadism. Many studies have described 
the beneficial effects and concerns of GH replacement therapy in 
children with PWS. Overall, GH treatment, when coupled with a 
strictly controlled diet in early childhood, may help to reduce obesity, 
improve neurodevelopment, and increase muscle mass. However, 
long-term safety studies need to be conducted, particularly with 
regard to the effects of GH treatment on glucose metabolism and 
scoliosis. Thyroid hormone levels should be regularly monitored in 
PWS children, particularly during GH treatment. Glucocorticoid 
treatment should be considered during intercurrent illness in PWS 
patients without a recently proven normal adrenal function. In 
conclusion, a more active approach for correcting these hormone 
deficiencies would benefit PWS patients.
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